2018’s Top Performing ETF Is Risky As Heck, But It Looks Like A Winner
I originally profiled the Loncar Cancer Immunotherapy ETF (CNCR) around two years ago. My general opinion at the time was that the immunotherapy category had great potential to turn into a blockbuster market, but CNCR wasn’t necessarily […]